AstraZeneca's Ultomiris won FDA approval for use in certain adults with IgA kidney disease, giving the drug another use and a chance to reach more patients. The approval covers a specific group, and the story gives no sales estimate, so the size of the benefit is unknown.
This gives Ultomiris another group of patients it can be used for, creating room for added sales. The approval covers adults at risk of worsening kidney disease, and the story gives no sales estimate, so the size of the benefit is unknown.
Follow AstraZeneca (AZN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for AZN